Chiltern to Acquire Theorem Clinical Research

UK-based global contract research organization (CRO) Chiltern has agreed to acquire Theorem Clinical Research, another CRO. Financial terms were not disclosed.

The merged operations will trade under the name Chiltern and employ 3,700 people in more than 45 companies.

Together, the two formerly separate companies currently said to be operating in complementary niches are planned to achieve global reach – both geographically and in areas of application.

The new Chiltern is expected to be especially strong in China and Japan, and the combination also is expected to broaden the constituent companies’ portfolio of services in the fields of medical devices and diagnostics, clinical analytics and clinical supply.

According to Chiltern CEO Jim Esinhart, the merger “is in direct response to client demand for a clinical research partner that can provide scientific and operating strengths globally, in a responsive and flexible way.”

Calling the acquisition by Chiltern “a mutually beneficial deal,” Theorem CEO John Potthoff said, “in key areas, our capability will dovetail into current Chiltern operations.”

Following antitrust approval, the transaction is due to be completed within the next several weeks.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.